Pilot study of the safety and efficacy of Myobloc™ (botulinum toxin type B) for treatment of xillary hyperhidrosis

International Journal of Dermatology

Volumn 44, Issue 5, 2005, Pages 418-424

  Baumann, Leslie S ^a   Slezinger, Anele ^a   Halem, Monica ^a   Vujevich, Justin ^a   Martin, Lucy K ^a   Black, Laura ^a   Bryde, Joy ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN B; HUMAN ALBUMIN; PLACEBO; SODIUM CHLORIDE; SUCCINIC ACID;

ACNE; ADULT; AGED; ARTICLE; AXILLA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRY EYE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HUMAN; HYPERHIDROSIS; INDIGESTION; INJECTION PAIN; MALE; MIGRAINE; OUTCOMES RESEARCH; OUTPATIENT CARE; PILOT STUDY; PRIVATE HOSPITAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SCREENING TEST; SKIN BRUISING; STATISTICAL SIGNIFICANCE; SWEATING; VOLUNTEER; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AXILLA; BOTULINUM TOXINS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERHIDROSIS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 18844397589     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2004.02531.x     Document Type: Article

References (14)

1. Naver H, Aquilonius SM. The treatment of focal hyperhidrosis with botulinum toxin. Eur J Neurol 1997; 4: 75-79.
2. Rompel R, Peros I, Petres J. Subcutaneous curettage for the treatment of axillary hyperhidrosis. Eur J Dermatol 1997; 7: 43-46.
3. Heckmann M, Breit S. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 1999; 41: 987-990.
4. Gossot D, Kabiri H, Caliandro R, et al. Early complications of thoracic endoscopic sympathectomy: A prospective study of 940 procedures. Ann Thorac Surg 2001; 71: 1116-1119.
5. Lai TY. Complications in patients with palmar hyperhidrosis treated with transthoracic endoscopic sympathectomy. Neurosurgery 1997; 41: 110-113.
6. Odderson IR. Axillary hyperhidrosis: Treatment with botulinum toxin A. Arch Phys Med Rehabil 1998; 79: 350-352.
7. Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox. Dermatol Surg 1998; 24: 817-819.
8. Schwetz BA. First drug for cervical dystonia. JAMA 2001; 285: 724.
9. Dressler D. Botulinum toxin type B for the treatment of axillary hyperhidrosis. J Neurol 2002; 249: 1729-1732.
10. Baumann L, Slezinger A, Vujevich J, et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc™ (Botulinum toxin type B) purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial. Dermatol Surg 2003; 29: 508-515.
11. Sadick NS. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 2001; 28: 817-821.
12. Naumann M, Lowe NJ, Kumar CR, et al. Hyperhidrosis Clinical Investigators Group. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003; 139: 731-736.
13. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49: 34-38.
14. Hund M, Kinkelin I, Naumann M, et al. Definition of axillary hyperhidrosis by gravimetric assessment. Arch Dermatol 2002; 138: 539-541.